Related Experiment Video
Updated: Jul 18, 2026
Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke
Published on: January 3, 2025
Doxycycline inhibits MMPs via modulation of plasminogen activators in focal cerebral ischemia
Dorothe Burggraf1, Andreas Trinkl, Martin Dichgans
1Department of Neurology, Ludwig-Maximilians University, Klinikum Grosshadern, Marchioninistr. 15, 81377 Munich, Germany.
Abstract:
Tetracyclines inhibit matrix metalloproteinases (MMPs) and reduce infarction volume following cerebral ischemia. In this thesis an involvement of urokinase could be proven. Cerebral ischemia in rats was induced for 3 h followed by 24 h reperfusion (suture model). Each 6 animals received orally either doxycycline or water. Doxycycline treatment began 10 days before ischemia. MMP-2 and MMP-9 were substantially decreased. The possibility of involvement of the endogenous MMP inhibitors in the MMP inhibiting mechanisms was excluded. The plasminogen activator uPA was significantly decreased by doxycycline indicating an MMP inhibiting mechanism including the plasminogen/plasmin system. In the doxycycline group, this resulted in a decreased damage to the cerebral microvessels and less loss of the basal lamina antigen collagen type IV. Hemoglobin extravasation was also significantly reduced. Our results suggest that doxycycline may have a potential use as an anti-ischemic compound since it provides microvascular protection by inhibiting the plasminogen system.
Insights
Doxycycline, a tetracycline, reduces brain damage after ischemic stroke by inhibiting matrix metalloproteinases (MMPs) and the urokinase plasminogen activator (uPA) system, protecting cerebral microvessels.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Tetracyclines, including doxycycline, are known to inhibit matrix metalloproteinases (MMPs).
- Cerebral ischemia leads to infarction and microvascular damage, partly mediated by MMPs.
- The role of the urokinase plasminogen activator (uPA) system in cerebral ischemia and its interaction with MMPs requires further elucidation.
Purpose of the Study:
- To investigate the effect of doxycycline on MMPs and the uPA system in a rat model of cerebral ischemia.
- To determine if doxycycline's neuroprotective effects involve the plasminogen/plasmin system.
- To assess doxycycline's impact on cerebral microvascular integrity and blood-brain barrier permeability.
Main Methods:
- Cerebral ischemia was induced in rats using a suture model (3 hours ischemia, 24 hours reperfusion).
- Animals received oral doxycycline or water for 10 days prior to and during ischemia.
- MMP-2, MMP-9, urokinase plasminogen activator (uPA), collagen type IV, and hemoglobin extravasation were measured.
Main Results:
- Doxycycline significantly decreased MMP-2 and MMP-9 levels.
- Doxycycline treatment led to a significant reduction in uPA activity.
- Microvascular damage, collagen type IV loss, and hemoglobin extravasation were significantly reduced in the doxycycline group.
Conclusions:
- Doxycycline exhibits neuroprotective effects in cerebral ischemia, likely through MMP and uPA inhibition.
- The mechanism involves protection of cerebral microvessels and the basal lamina.
- Doxycycline's ability to inhibit the plasminogen system suggests potential as an anti-ischemic therapeutic agent.
